Biography
Matthew Gubens, MD, MS, FASCO is Professor of Medicine at UCSF, where he practices as a thoracic medical oncologist and serves as Medical Director of Thoracic Medical Oncology. He is also Chair of the UCSF Cancer Center Protocol Review and Monitoring Committee which oversees scientific review of clinical cancer research at the institution. Dr. Gubens is Immediate Past Chair of the ASCO Evidence Based Medicine Committee which oversees the ASCO Guidelines program, and he also co-chairs the ASCO Thoracic Guideline Advisory Group. Dr. Gubens serves on the National Comprehensive Cancer Network panels for non-small cell lung cancer, mesothelioma, and thymic malignancies. He is on the Board of Directors of the Association of Northern California Oncologists. Dr Gubens completed his BA at Yale, his MS at the Harvard School of Public Health, and his MD at Stanford, and trained in internal medicine residency at UCSF and then medical oncology at Stanford.
Education
Institution | Degree | Dept or School | End Date |
---|---|---|---|
Stanford University | Fellowship | School of Medicine - Medical Oncology | 2011 |
University of California, San Francisco | Residency | School of Medicine - Internal Medicine | 2008 |
Stanford University | M.D. | School of Medicine | 2005 |
Harvard School of Public Health | M.S. | Health Policy and Management | 2000 |
Yale University | B.A. | Ethics, Politics and Economics | 1997 |
Board Certifications
American Board of Internal Medicine, Internal Medicine
Clinical Expertise
Bronchioloalveolar Carcinoma (BAC)
Chest Wall Tumors
Lung Carcinoid Tumors
Lung Metastases
Malignant Mesothelioma
Mediastinal Tumors
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Thymoma & Thymic Carcinoma
Clinical Trials
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (NCT04185883)Related Conditions: Solid Tumor, Sarcoma, Neoplasms| Start Date: | End Date:
- Related Conditions: Lung Cancer, Non-Small Cell Lung Cancer| Start Date: | End Date:
- Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (NCT03710876)Related Conditions: Mesothelioma, Adenovirus| Start Date: | End Date:
- Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer (NCT04061590)Related Conditions: Non-Small Cell Lung Cancer, Small Cell Carcinoma, Lung Cancer, Immunotherapy, Lung Tumor| Start Date: | End Date:
- TG4010 and Nivolumab in Patients With Lung Cancer (NCT02823990)Related Conditions: Lung Cancer, Non-Small Cell Lung Cancer, Lung Tumor| Start Date: | End Date:
Program Affiliations
Department of Medicine, Division of Hematology Oncology
Thoracic Oncology Program
UCSF Helen Diller Family Comprehensive Cancer Center
Research Interests
Thymoma & Thymic Carcinoma
Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 70
- Proceedings of the 1st biannual bridging the gaps in lung cancer conference.| | PubMed
- Real-World Biomarker Test Ordering Practices in Non-Small Cell Lung Cancer: Interphysician Variation and Association With Clinical Outcomes.| | PubMed
- Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.| | PubMed
- Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.| | PubMed
- American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non-Small Cell Lung Cancer.| | PubMed
- Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology| | PubMed
- Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.| | PubMed
- NCCN Guidelines® Insights: Mesothelioma: Pleural, Version 1.2024.| | PubMed
- Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors.| | PubMed
- Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.| | PubMed
- Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.| | PubMed
- Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.| | PubMed
- American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma.| | PubMed
- NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.| | PubMed
- Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study.| | PubMed
- Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC.| | PubMed
- The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study.| | PubMed
- Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.| | PubMed
- Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.| | PubMed
- Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study.| | PubMed
- Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.| | PubMed
- Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer.| | PubMed
- Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.| | PubMed
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.| | PubMed
- Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer.| | PubMed
- Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.| | PubMed
- Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.| | PubMed
- Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.| | PubMed
- Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.| | PubMed
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.| | PubMed
- Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.| | PubMed
- Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.| | PubMed
- NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer.| | PubMed
- Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.| | PubMed
- Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.| | PubMed
- Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.| | PubMed
- Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.| | PubMed
- ALK Testing Trends and Patterns Among Community Practices in the United States.| | PubMed
- NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.| | PubMed
- Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study.| | PubMed
- Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.| | PubMed
- 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.| | PubMed
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.| | PubMed
- Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.| | PubMed
- A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.| | PubMed
- Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.| | PubMed
- Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer.| | PubMed
- Immunotherapies for Lung Cancer.| | PubMed
- Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.| | PubMed
- Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.| | PubMed
- Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution.| | PubMed
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.| | PubMed
- An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer.| | PubMed
- Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.| | PubMed
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.| | PubMed
- A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay.| | PubMed
- Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.| | PubMed
- A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies.| | PubMed
- Pembrolizumab for the treatment of non-small-cell lung cancer.| | PubMed
- NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.| | PubMed
- A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors.| | PubMed
- Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer.| | PubMed
- Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.| | PubMed
- Treatment updates in advanced thymoma and thymic carcinoma.| | PubMed
- Long-term survivors of gastric cancer: a California population-based study.| | PubMed
- Current management of small cell lung cancer.| | PubMed
- Lymphoma in pregnancy initially diagnosed as vaginal intraepithelial neoplasia and lichen planus.| | PubMed
- Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis.| | PubMed
- Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction.| | PubMed
- Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness.| | PubMed